Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) therapy has revolutionized anti-cancer therapy, with lung cancer exhibiting sustained clinical responses to it. However, there remains a lack of research into the risk factors of serious infections in patients with lung cancer following ICIs therapy. Therefore, we aimed to investigate the incidence and risk factors of serious infections in these patients.

Methods

Medical records were retrospectively collected and reviewed from 710 patients with lung cancer receiving ICIs therapy at Zhongshan Hospital between January 2021 and February 2023. Serious infections were defined as infections requiring hospitalization or parenteral antimicrobials occurring at any time from the initiation of the ICIs therapy to 3 months after its discont

SUBMITTER: Wang X 

PROVIDER: S-EPMC11843754 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature